Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
van der Werf
Christian
C
Wilde
Arthur A M
AA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002395:Catecholamines / Q000378:metabolism; D017147:Defibrillators, Implantable; D005424:Flecainide / Q000627:therapeutic use*; D005817:Genetic Counseling; D005820:Genetic Testing; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D051379:Mice; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000235:genetics*; D017180:Tachycardia, Ventricular / Q000235:genetics / Q000517:prevention & control / Q000628:therapy; D000098850:Polymorphic Catecholaminergic Ventricular Tachycardia
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D002395:Catecholamines; D019837:Ryanodine Receptor Calcium Release Channel; D005424:Flecainide